Wednesday, January 7, 2009

Transgene Biotek's Net Profit Fell - Jan 7, 2009

The scrip has risen 39.38% in six trading sessions from a recent low of Rs 17.65 on 30 December 2008.

Meanwhile, the BSE Sensex was down 16.63 points, or 0.16%, to 10,319.30.

On BSE, 24,050 shares were traded in the counter. The stock had an average daily volume of 11,148 shares in the past one quarter.

The stock hit a high of Rs 24.60 and a low of Rs 23.50 so far during the day. The stock hit a 52-week high of Rs 115.60 on 8 January 2008 and a 52-week low of Rs 14.55 on 3 November 2008.

The small-cap stock had outperformed the market over the past one month till 6 January 2009, gaining 25.14% as compared to the Sensex's return of 15.29%. It had also outperformed the market in the past one quarter, falling 4.48% as compared to the Sensex's decline of 12.42%.

The company's current equity is Rs 15.77 crore. Face value per share is Rs 10.

The current price of Rs 24.60 discounts the company's Q2 September 2008 annualized EPS of Rs 0.24, by a PE multiple of 102.05.

Transgene Biotek said during trading hours on on 2 January 2009 that it had received manufacturing license from the Drug Control Department of Hyderabad for manufacturing four drugs Orlistat, Lovastatin, Simvastatin and Pravastatin. These drugs are used to control cholesterol in blood.

The company had on 30 December 2008 signed a pact with Heber Biotec S.A, Havana, Cuba for the development and commercialization of three different drugs.

Transgene Biotek's net profit fell 75% to Rs 0.09 crore on 2.3% increase in net sales to Rs 0.89 crore in Q2 September 2008 over Q2 September 2007.

The company is engaged in the research and development and manufacture of various medical reagents, both chemical and immuno-diagnostic reagents for the qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases.

No comments: